Subscribe
shutterstock_1349460611_pavel_kapysh-1-1
Pavel Kapysh / Shutterstock.com
18 August 2022AmericasStaff Writer

Bausch Health unit prevails in patent dispute

New Jersey court dismissed a suit regarding an oral antibiotic | Prior art invalidated plaintiff’s four patents.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Pharma unit could get green light to launch IBS generic
2 August 2022   Dispute centres on Xifaxan, used to treat irritable bowel syndrome | ‘Significant hurdle’ cleared in bringing drug to market | Bausch wins partial victory after Alvogen subsidiary failed to show that patent claims were obvious.
Americas
Bausch targets Israeli firm in skin treatment dispute
22 June 2023   Pharma company claims infringement of both patents that cover the blockbuster treatment | Generic version has been in motion since May last year.
Big Pharma
Bausch Ireland fends off challenge to its cancer patent
12 September 2023   Pharma firm fails to show evidence to prove obviousness in rival’s patent | Treatment can be used to treat cancer as well as ulcerative colitis and asthma.


Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Americas
Litigation implications of the USPTO’s terminal disclaimer proposal
29 August 2024
Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Europe
Labour govt appoints new Minister with IP oversight
9 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024

More on this story

Americas
Pharma unit could get green light to launch IBS generic
2 August 2022   Dispute centres on Xifaxan, used to treat irritable bowel syndrome | ‘Significant hurdle’ cleared in bringing drug to market | Bausch wins partial victory after Alvogen subsidiary failed to show that patent claims were obvious.
Americas
Bausch targets Israeli firm in skin treatment dispute
22 June 2023   Pharma company claims infringement of both patents that cover the blockbuster treatment | Generic version has been in motion since May last year.
Big Pharma
Bausch Ireland fends off challenge to its cancer patent
12 September 2023   Pharma firm fails to show evidence to prove obviousness in rival’s patent | Treatment can be used to treat cancer as well as ulcerative colitis and asthma.

More on this story

Americas
Pharma unit could get green light to launch IBS generic
2 August 2022   Dispute centres on Xifaxan, used to treat irritable bowel syndrome | ‘Significant hurdle’ cleared in bringing drug to market | Bausch wins partial victory after Alvogen subsidiary failed to show that patent claims were obvious.
Americas
Bausch targets Israeli firm in skin treatment dispute
22 June 2023   Pharma company claims infringement of both patents that cover the blockbuster treatment | Generic version has been in motion since May last year.
Big Pharma
Bausch Ireland fends off challenge to its cancer patent
12 September 2023   Pharma firm fails to show evidence to prove obviousness in rival’s patent | Treatment can be used to treat cancer as well as ulcerative colitis and asthma.

More features

Gilead scores win in fake HIV drug dispute
Polsinelli grows roster with ex-corporate counsel
‘Don’t rely on national case law’ at the UPC: Wouter Pors, Bird & Bird
Sandoz wins $137.2m payout for lost profits in generic launch
Sanofi signs global rights deal to develop rare cancer therapy
Unified Patent Court visualised: Cases, divisions, and classes in charts
WBD to merge with firm to create ‘powerhouse’ practice
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers